Prosecution Insights
Prosecution Insights
26 pending office actions • 18 art units • 24 examiners • 0 of 26 (0%) have an AI response strategy ready • 11 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 13 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 13 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 4 (15%) |
| §101 + other | 5 (19%) |
| §103 only | 5 (19%) |
| §102 only | 2 (8%) |
| §112 only | 4 (15%) |
| Double-patenting only | 1 (4%) |
| Multi-statute (no §101) | 5 (19%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HANEY, AMANDA MARIE | 3 | 36.5% | +44.5% |
| LANNU, JOSHUA DARYL DEANON | 1 | 82.4% | +23.9% |
| HYDER, G.M. ALI | 1 | 90.6% | +7.3% |
| ABUZEINEH, HANAN ISAM | 1 | 56.0% | +51.4% |
| GURLEY, JAMI MICHELLE | 1 | 54.2% | +14.3% |
| LAMPRECHT, JOEL | 1 | 81.3% | +16.9% |
| NGUYEN, HENRY H | 1 | 63.8% | +36.9% |
| BELL, SARA ELIZABETH | 1 | 69.1% | +38.2% |
| PECKHAM, RICHARD GRANT | 1 | 67.2% | +37.0% |
| BUCHANAN, BAILEY CHEYENNE | 1 | 47.6% | +50.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19288971 | MONITORING ORGAN MORPHOLOGY FOR RADIATION TREATMENT DELIVERY USING ULTRASOUND | LANNU, JOSHUA DARYL DEANON | 12d |
| 18864266 | MULTISPECTRAL MAGNETIC RESONANCE IMAGING ENHANCEMENT USING SPECTRAL ACQUISITION REDUNDANCY | HYDER, G.M. ALI | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17493230 | ASSESSING CONDITIONS IN TRANSPLANT SUBJECTS USING DONOR-SPECIFIC CELL-FREE DNA | HANEY, AMANDA MARIE | 141d overdue |
| 17427005 | Systems and Methods for Sound Mapping of Anatomical and Physiological Acoustic Sources Using an Array of Acoustic Sensors | PORTILLO, JAIRO H | 88d overdue |
| 16623719 | ASSESSING CONDITIONS IN TRANSPLANT SUBJECTS USING DONOR-SPECIFIC CELL-FREE DNA | HANEY, AMANDA MARIE | 2d overdue |
| 18578948 | Augmented Reality-Driven Guidance for Interventional Procedures | LAMPRECHT, JOEL | 12d |
| 17493186 | METHODS FOR ASSESSING RISK USING TOTAL CELL-FREE DNA | ALLEN, SARAH ELIZABETH | 12d |
| 18717658 | Indicator Clearance Monitoring in Machine Perfusion of an Organ | ABUZEINEH, HANAN ISAM | — |
| 18293455 | OSMR-SPECIFIC MONOCLONAL ANTIBODIES AND METHODS OF THEIR USE | GURLEY, JAMI MICHELLE | — |
| 18343097 | ASSESSING TRANSPLANT COMPLICATION RISK WITH TOTAL CELL-FREE DNA | BUCHANAN, BAILEY CHEYENNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17493230 | ASSESSING CONDITIONS IN TRANSPLANT SUBJECTS USING DONOR-SPECIFIC CELL-FREE DNA | HANEY, AMANDA MARIE | 141d overdue |
| 16623719 | ASSESSING CONDITIONS IN TRANSPLANT SUBJECTS USING DONOR-SPECIFIC CELL-FREE DNA | HANEY, AMANDA MARIE | 2d overdue |
| 19288971 | MONITORING ORGAN MORPHOLOGY FOR RADIATION TREATMENT DELIVERY USING ULTRASOUND | LANNU, JOSHUA DARYL DEANON | 12d |
| 18578948 | Augmented Reality-Driven Guidance for Interventional Procedures | LAMPRECHT, JOEL | 12d |
| 16623725 | TRANSPLANT PATIENT MONITORING WITH CELL-FREE DNA | HANEY, AMANDA MARIE | 27d |
| 18287632 | Quinazoline Derivatives, Pharmaceutical Compositions, and Therapeutic Uses Related to Nox Inhibition | BELL, SARA ELIZABETH | 79d |
| 18717658 | Indicator Clearance Monitoring in Machine Perfusion of an Organ | ABUZEINEH, HANAN ISAM | — |
| 18293455 | OSMR-SPECIFIC MONOCLONAL ANTIBODIES AND METHODS OF THEIR USE | GURLEY, JAMI MICHELLE | — |
| Art Unit | Apps |
|---|---|
| 1682 | 4 |
| 3791 | 2 |
| 1685 | 2 |
| 3798 | 1 |
| 1758 | 1 |
| 1625 | 1 |
| 1627 | 1 |
| 1658 | 1 |
| 3771 | 1 |
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19288971 | MONITORING ORGAN MORPHOLOGY FOR RADIATION TREATMENT DELIVERY USING ULTRASOUND | LANNU, JOSHUA DARYL DEANON | 3791 | §103 | Non-Final OA | 12d | Pending | Aug 01, 2025 |
| 18864266 | MULTISPECTRAL MAGNETIC RESONANCE IMAGING ENHANCEMENT USING SPECTRAL ACQUISITION REDUNDANCY | HYDER, G.M. ALI | — | §112 | Non-Final OA | — | Pending | Nov 08, 2024 |
| 18717658 | Indicator Clearance Monitoring in Machine Perfusion of an Organ | ABUZEINEH, HANAN ISAM | — | §102§103 | Non-Final OA | — | Pending | Jun 07, 2024 |
| 18293455 | OSMR-SPECIFIC MONOCLONAL ANTIBODIES AND METHODS OF THEIR USE | GURLEY, JAMI MICHELLE | — | §103§112 | Non-Final OA | — | Pending | Jan 30, 2024 |
| 18578948 | Augmented Reality-Driven Guidance for Interventional Procedures | LAMPRECHT, JOEL | 3798 | §102§103 | Non-Final OA | 12d | Pending | Jan 12, 2024 |
| 18497541 | METHODS FOR ASSESSING CELLULAR OR TISSUE INJURY USING MITOCHONDRIAL AND/OR NUCLEAR CELL-FREE DNA | NGUYEN, HENRY H | 1758 | DP | Non-Final OA | — | Pending | Oct 30, 2023 |
| 18287632 | Quinazoline Derivatives, Pharmaceutical Compositions, and Therapeutic Uses Related to Nox Inhibition | BELL, SARA ELIZABETH | 1625 | §112 | Non-Final OA | 79d | Pending | Oct 19, 2023 |
| 18546143 | Small Molecule Inhibitors of PBRM1-BD2 | PECKHAM, RICHARD GRANT | 1627 | §102 | Final Rejection | — | Pending | Aug 11, 2023 |
| 18343097 | ASSESSING TRANSPLANT COMPLICATION RISK WITH TOTAL CELL-FREE DNA | BUCHANAN, BAILEY CHEYENNE | 1682 | §101§102§103§112Other | Non-Final OA | — | Pending | Jun 28, 2023 |
| 18035921 | ASSESSING RISK WITH PRE-OPERATIVE TOTAL CELL-FREE DNA | KALLAL, ROBERT JAMES | 1685 | §101§102§103§112 | Non-Final OA | — | Pending | May 08, 2023 |
| 18252073 | Peptide Inhibitors of Human Mitochondrial Fission Protein 1 and Methods of Use | REYNOLDS, FRED H | 1658 | §112 | Non-Final OA | 14d | Pending | May 08, 2023 |
| 18040459 | Embolic Protection System | RIVERS, LINDSEY RAE | 3771 | §103 | Final Rejection | 53d overdue | Pending | Feb 03, 2023 |
| 18005802 | Multiple Myeloma Mapping and Uses Thereof | DENT, ALANA HARRIS | 1643 | §102§103§112 | Non-Final OA | — | Pending | Jan 17, 2023 |
| 18057494 | COMPOSITIONS AND METHODS FOR REDUCING CELL-FREE DNA | SMITH, PETER DANIEL | 3781 | §103 | Non-Final OA | 28d overdue | Pending | Nov 21, 2022 |
| 17965148 | Assay to Differentiate Natural CMV Infection from CMV Vaccines that Lack UL144 | BLUMEL, BENJAMIN P | 1671 | §102§103§112 | Final Rejection | — | Pending | Oct 13, 2022 |
| 17911022 | 3-(2-(Aminoethyl)-Indol-4-ol Derivatives, Methods of Preparation Thereof, and the Use as 5-HT2 Receptor Modulators | BURKETT, DANIEL JOHN | 1624 | §102 | Non-Final OA | 46d overdue | Pending | Sep 12, 2022 |
| 17817561 | TRAUMA-INTERVENTION DETERMINATION | KHATTAR, RAJESH | 3684 | §101 | Final Rejection | — | Pending | Aug 04, 2022 |
| 17493293 | TRANSPLANT PATIENT MONITORING WITH CELL-FREE DNA | RYAN, DOUGLAS CHARLES | 1635 | §101§102§103§112 | Non-Final OA | — | Pending | Oct 04, 2021 |
| 17493186 | METHODS FOR ASSESSING RISK USING TOTAL CELL-FREE DNA | ALLEN, SARAH ELIZABETH | 1637 | §101§103Other | Final Rejection | 12d | Pending | Oct 04, 2021 |
| 17493230 | ASSESSING CONDITIONS IN TRANSPLANT SUBJECTS USING DONOR-SPECIFIC CELL-FREE DNA | HANEY, AMANDA MARIE | 1682 | §101§103§112DP | Final Rejection | 141d overdue | Pending | Oct 04, 2021 |
| 17442968 | Tip60 Inhibitors and Methods of Use for Cardiovascular Disease | BARSKY, JARED | 1628 | §103 | Non-Final OA | 15d | Pending | Sep 24, 2021 |
| 17427005 | Systems and Methods for Sound Mapping of Anatomical and Physiological Acoustic Sources Using an Array of Acoustic Sensors | PORTILLO, JAIRO H | 3791 | §101 | Non-Final OA | 88d overdue | Pending | Jul 29, 2021 |
| 17297075 | Methods and Systems for In Vitro Cardiac Disease Modeling | REGLAS, GILLIAN CHELSEA | 1632 | §112 | Final Rejection | — | Pending | May 26, 2021 |
| 16623725 | TRANSPLANT PATIENT MONITORING WITH CELL-FREE DNA | HANEY, AMANDA MARIE | 1682 | §103 | Final Rejection | 27d | Pending | Dec 17, 2019 |
| 16623719 | ASSESSING CONDITIONS IN TRANSPLANT SUBJECTS USING DONOR-SPECIFIC CELL-FREE DNA | HANEY, AMANDA MARIE | 1682 | §101Other | Final Rejection | 2d overdue | Pending | Dec 17, 2019 |
| 16666210 | HIGHLY SENSITIVE TRANSPLANT REJECTION SURVEILLANCE USING TARGETED DETECTION OF DONOR SPECIFIC CELL FREE DNA | MINCHELLA, KAITLYN L | 1685 | §101Other | Non-Final OA | — | Pending | Oct 28, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial